Article
Biochemistry & Molecular Biology
Mun Gyeong Bae, Jeon Hwang-Bo, Dae Young Lee, Youn-Hyung Lee, In Sik Chung
Summary: The research shows that 6,8-DG inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis by suppressing VEGF-A expression in cancer cells and the VEGF-A/VEGFR-2 signaling pathway in HLMEC. Therefore, 6,8-DG could be a novel and valuable therapeutic agent for metastasis prevention and treatment of oral cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
James R. Miller, Serigne N. Lo, Mehdi Nosrati, Jonathan R. Stretch, Andrew J. Spillane, Robyn P. M. Saw, Kerwin F. Shannon, Omgo E. Nieweg, Sydney Ch'ng, Kevin B. Kim, Stanley P. Leong, John F. Thompson, Richard A. Scolyer, Mohammed Kashani-Sabet
Summary: By refining eligibility guidelines, more appropriate patients can be identified to undergo useful medical procedures, improving cost-effectiveness in selecting patients with melanoma for sentinel lymph node biopsy (SLNB).
Article
Surgery
Erika G. Kusajima, Yuhei Yamamoto, Kosuke Ishikawa, Takahiro Miura, Emi Funayama, Masayuki Osawa, Ryo Takagi, Taku Maeda
Summary: This study investigated the impact of vascularized lymph node transfer (VLNT) on dendritic cell (DC) dynamics against cancer in mouse models. It was found that mice with reconnected lymphatics after VLNT had reduced metastasis and an increased proportion of DCs, suggesting that VLNT may enhance the tumor immune response by promoting DC migration to lymph nodes.
Article
Medicine, General & Internal
Franco Picciotto, Gianluca Avallone, Federico Castellengo, Martina Merli, Virginia Caliendo, Rebecca Senetta, Adriana Lesca, Desiree Deandreis, Maria Teresa Fierro, Pietro Quaglino, Simone Ribero
Summary: Sentinel lymph node biopsy is an effective staging procedure, but the current classification may result in inaccurate staging. A new surgical technique combined with SPECT-CT can better guide surgeons to improve staging accuracy for melanoma patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Ya Liu, Limin Pan, Yuxi Li, Yuying Deng, Xue Han, Han Fu, Tianxiao Wang
Summary: The CBS/H2S system plays a crucial role in lymph node metastasis of esophageal squamous cell carcinoma (ESCC), promoting lymph node metastasis by activating the SIRT1 signaling pathway. Moreover, CBS also affects angiogenesis and lymphangiogenesis in ESCC.
Article
Multidisciplinary Sciences
Hyo Jin Kang, Soo Young Moon, Baek-Kyu Kim, Yujin Myung, Ju-Hee Lee, Jae Hoon Jeong
Summary: To overcome the limitations of lymphedema treatment, human adipose-derived stem cells (hADSCs) were injected into decellularized lymph nodes to produce a recellularized lymph node-scaffold, and the effect of lymphangiogenesis was investigated in lymphedema animal models.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Titus J. Brinker, Lennard Kiehl, Max Schmitt, Tanja B. Jutzi, Eva I. Krieghoff-Henning, Dieter Krahl, Heinz Kutzner, Patrick Gholam, Sebastian Haferkamp, Joachim Klode, Dirk Schadendorf, Achim Hekler, Stefan Froehling, Jakob N. Kather, Sarah Haggenmueller, Christof von Kalle, Markus Heppt, Franz Hilke, Kamran Ghoreschi, Markus Tiemann, Ulrike Wehkamp, Axel Hauschild, Michael Weichenthal, Jochen S. Utikal
Summary: The study aimed to develop a digital biomarker for predicting lymph node metastasis non invasively from digitised H&E slides of primary melanoma tumors. Artificial neural networks were trained and tested, achieving the best accuracy of 61.8% but with limited clinical relevance.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Dermatology
Julia Huynh, Ulrike Leiter, Claus Garbe, Galina Shiderova, Vincent Walter, Thomas Eigentler, Alexander Scheu, Hans-Martin Haefner, Saskia Maria Schnabl
Summary: This study investigated the use of sentinel lymph node biopsy in patients with lentigo maligna melanoma and tumor thickness ≥1 mm. The results showed that sentinel lymph nodes were positive in 12.7% of cases. There was no significant difference in distant metastasis-free survival and overall survival between patients with and without sentinel lymph node biopsy.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Oncology
Zeynep Eroglu, Kristy K. Broman, John F. Thompson, Amanda Nijhuis, Tina J. Hieken, Lisa Kottschade, Jeffrey M. Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K. Bartlett, Avinash Sharma, Lesly Dossett, Tasha Hughes, David E. Gyorki, Jennifer Downs, Giorgos Karakousis, Yun Song, Ann Lee, Russell S. Berman, Alexander van Akkooi, Emma Stahlie, Dale Han, John Vetto, Georgia Beasley, Norma E. Farrow, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, Michael Lowe, David W. Ollila, Frances A. Collichio, Roger Olofsson Bagge, Jan Mattsson, Hidde M. Kroon, Harvey Chai, Jyri Teras, James Sun, Michael J. Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi, Jonathan Zager, Nikhil Khushalani
Summary: Most patients with SLN+ melanoma no longer undergo a completion lymph node dissection (CLND) prior to adjuvant systemic therapy. The omission of immediate CLND in these patients may increase the risk of nodal relapse, but salvage surgery with therapeutic lymph node dissection (TLND) at relapse may be a viable option for these patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Katherine M. Marsh, Courtney M. Lattimore, Christopher L. Cramer, Craig L. Slingluff, Lynn T. Dengel
Summary: This study reports cases of primary melanoma draining to subcostal lymph nodes and provides characterization of the locations of these nodes. The study found that subcostal nodes are typically located under ribs 10-12 and have size limitations.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Surgery
Daniel Wen, Richard C. W. Martin
Summary: The study conducted a retrospective quality audit of sentinel lymph nodal biopsy (SLNB) practices in melanoma patients, showing a high rate of SN identification and a FNR of 9.1%. SLNB is considered the best staging tool for melanoma, providing potential access to adjuvant systemic treatment for patients.
ANZ JOURNAL OF SURGERY
(2021)
Article
Oncology
Kelsey B. Montgomery, Tanya A. Correya, Kristy K. Broman
Summary: The adherence to nodal surveillance ultrasound (US) remains unknown in real-world practice for patients with sentinel lymph node-positive (SLN+) melanoma. This study found that adjuvant therapy appears to be associated with a decreased likelihood of US adherence.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Cell Biology
Tiffany W. Cheng, Emily Hartsough, Alessio Giubellino
Summary: Assessment of sentinel lymph node status is crucial for melanoma patients' prognosis and therapeutic management, and pathologists play a vital role in this evaluation. Various methods have been used, including evaluating metastatic burden dimensions, determining tumor deposit locations within lymph nodes, and precise cell counting. However, no single method can independently predict prognosis. The management approach for sentinel lymph node-positive patients has also evolved, with a more conservative approach recognized for selected cases. This review provides an overview of past and current advancements in the field, along with potential future directions based on prior experiences and clinical trials.
Article
Oncology
Hanna Kakish, Trisha Lal, Jason E. Thuener, Jeremy S. Bordeaux, Ankit Mangla, Luke D. Rothermel, Richard S. Hoehn
Summary: This study evaluated the utility and prognostic value of sentinel lymph node biopsy (SLNB) in lentigo maligna melanoma (LMM) using large databases. The results showed that SLNB was associated with improved overall survival (OS) but not melanoma-specific survival (MSS) in LMM patients.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont
Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Dermatology
N. Van den Berghe, E. De Keyser, R. Soenen, L. Meuleman, S. Lanssens, A. Gils, J. Lambert
BRITISH JOURNAL OF DERMATOLOGY
(2020)
Article
Dermatology
J. L. W. Lambert, S. Segaert, P. D. Ghislain, T. Hillary, A. Nikkels, F. Willaert, J. Lambert, R. Speeckaert
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2020)
Article
Dermatology
J. L. W. Lambert, S. Segaert, P. D. Ghislain, T. Hillary, A. Nikkels, F. Willaert, J. Lambert, R. Speeckaert
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2020)
Article
Dermatology
Lisa Schots, Lynda Grine, Rani Soenen, Jo Lambert
Summary: This study shows that most dermatologists empirically adjust the dosage of biologics. The majority of dermatologists recognize the need for therapeutic drug monitoring (TDM), indicating the necessity for effective communication about the availability, utility, and implementation of TDM assays in daily dermatology practice.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Medicine, General & Internal
Jo L. W. Lambert, Sofie De Schepper, Reinhart Speeckaert
Summary: Biologics used in the treatment of Crohn's disease and ulcerative colitis can lead to various skin eruptions, especially those targeting TNF-alpha and Th17 pathway. It is important to recognize and adapt the treatment strategy accordingly to manage these adverse reactions effectively.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Michael Ablinger, Thomas Lettner, Nicole Friedl, Hannah Potocki, Theresa Palmetzhofer, Ulrich Koller, Julia Illmer, Bernadette Liemberger, Stefan Hainzl, Alfred Klausegger, Manuela Reisenberger, Jo Lambert, Mireille Van Gele, Eline Desmet, Els Van Maelsaeke, Monika Wimmer, Roland Zauner, Johann W. Bauer, Verena Wally
Summary: Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is a rare disease with heterogeneous mutations, making therapy development challenging. However, the use of AON to induce exon skipping shows promise as a personalized treatment approach for this condition.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Bart Sturm, David Creytens, Jan Smits, Ariadne H. A. G. Ooms, Erik Eijken, Eline Kurpershoek, Heidi V. N. Kuesters-Vandevelde, Carla Wauters, Willeke A. M. Blokx, Jeroen A. W. M. van der Laak
Summary: An increasing number of pathology laboratories are using whole slide imaging for routine diagnostics, which provides a pathway for the application of artificial intelligence in computer-aided diagnosis. This study applied a mitosis algorithm primarily developed for breast cancer to the diagnosis of melanocytic skin lesions and found that pathologists perform similarly with and without the aid of the algorithm in general cases. However, the algorithm improved the performance of pathologists in diagnosing nevoid melanoma cases.
Article
Health Care Sciences & Services
Lynda Grine, Niels Hilhorst, Nathalie Michels, Souheila Abbeddou, Stefaan De Henauw, Jo Lambert
Summary: This study aims to investigate the effects of MIF on skin, gut, and metabolic health in psoriasis patients. Through clinical and molecular research, we hope to understand the differences in psoriasis severity and gut health integrity between MIF and a regular diet, as well as how dietary lifestyles can impact the development of psoriasis.
JMIR RESEARCH PROTOCOLS
(2022)
Editorial Material
Dermatology
Deepak M. W. Balak, Jo Lambert
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Rani Soenen, Zhigang Wang, Lynda Grine, Erwin Dreesen, Lisa Schots, Els Brouwers, Paul Declerck, Debby Thomas, Jo Lambert
Summary: This study aimed to develop and validate an immunoassay for secukinumab and determine the therapeutic window in patients with psoriasis. The results showed that secukinumab trough concentrations decreased with increasing body mass index (BMI). The minimal effective threshold was found to be 39.1 mg/L, which was associated with a high probability of optimal clinical response. Monitoring and adjusting secukinumab trough concentration to 39.1 mg/L may be a viable treatment option for suboptimal responders.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Medicine, General & Internal
Rani Soenen, Christophe Stove, Alessio Capobianco, Hanne De Schutter, Marie Dobbelaere, Tahmina Mahjor, Merel Follens, Jo Lambert, Lynda Grine
Summary: Therapeutic drug monitoring (TDM) of biologics, including the measurement of drug concentrations and antibodies, is a valuable tool for clinical decision making. In this study, the feasibility and perception of home microsampling for quantification of adalimumab concentrations in psoriasis patients were evaluated. The results showed that lateral flow testing (LFT) and enzyme-linked immunosorbent assay (ELISA) provided consistent measurements. The study demonstrates the potential for TDM implementation for adalimumab using rapid testing and home-based microsampling.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Dermatology
Niels Timo Hilhorst, Elfie Deprez, Deepak Mukesh Wieshwaykumar Balak, Nanja Van Geel, Jan Gutermuth, Isabelle Hoorens, Jo Lydie Wilfried Lambert
Summary: This study aims to develop an actionable value-based outcome set (VOS) for evaluating psoriasis care. Through four phases of a mixed method approach, the study identified the outcomes deemed important by patients and selected suitable instruments to measure these outcomes. This VOS allows for the evaluation and improvement of current care processes, increasing value for patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Oncology
Melissa M. M. De Meza, Willeke A. M. Blokx, Johannes J. J. Bonenkamp, Christian U. U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. J. Van Not, Djura Piersma, Rozemarijn S. S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Summary: BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival in stage III melanoma patients with BRAF V600 mutations. This study aimed to compare the toxicity and survival outcomes of these therapies in daily practice. The results showed that grade >= 3 toxicity occurred in 11.5% of patients, leading to early treatment discontinuation in 71.1% of cases. At 12 months, patients treated with BRAF/MEK therapy had better progression-free survival than those treated with anti-PD-1 therapy, but this difference was no longer observed at 18 months.
Article
Dermatology
Jan Koren, Jo L. W. Lambert, Simon F. F. Thomsen, Helen McAteer, Gabriella Fabbrocini, Valeria Corazza, Denis Jullien, Matthias Augustin, Richard B. B. Warren, Menno A. A. de Rie, Elizabeth Lazaridou, Lluis Puig, Loic Guillevin, Marius Grosser, Wolf-Henning Boehncke
Summary: By combining the perspectives of patients, clinicians, and payors, we identified multiple themes to improve the standard of care for patients with psoriasis. Through a Delphi process, consensus was reached on these themes and a set of practical 'Calls to Action' were proposed. Improving healthcare systems, patient access, quality-of-life measures, relevance and reach of guidelines, and patient education were all recognized as important factors.
DERMATOLOGY AND THERAPY
(2023)
Article
Oncology
Olivier J. van Not, Thijs T. Wind, Rawa K. Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. Haanen, Ellen Kapiteijn, Manja Bloem, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Willeke A. M. Blokx, Karijn P. M. Suijkerbuijk, Rudolf S. N. Fehrmann, Geke A. P. Hospers
Summary: This study aimed to identify prognostic factors in advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors. The analysis found that the serum lactate dehydrogenase (LDH) level was the strongest clinical parameter associated with survival.